Progressive multifocal leukoencephalopathy (PML) is a rare but serious brain infection. It gradually destroys brain tissue and often leads to death within a few weeks. It is caused by the human ...

Please provide your email address to receive an email when new articles are posted on . Use of a genetic risk test for patients considering immunosuppressive therapies associated with development of ...

New research has confirmed a strong link between four genetic mutations and progressive multifocal leukoencephalopathy (PML), a rare but often fatal brain infection that can be triggered by dozens of ...

A new study found dozens of FDA approved drugs can increase the risk of developing progressive multifocal leukoencephalopathy, a rare and often fatal brain infection, by an average of eight times. The ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...

Background Progressive multifocal leukoencephalopathy (PML) is associated with natalizumab treatment. We quantified the risk of PML in patients with multiple sclerosis, according to the presence or ...

Presence and function of CD14+CD16-HLADRlow monocytes in the peripheral blood of patients with Β-cell non-Hodgkin lymphoma (NHL). Mean age in years at death (sd) 65.1 years (6.9) 67.3 years (6.6) Mean ...

Progressive multifocal leukoencephalopathy (PML) is a rare but serious brain infection. It gradually destroys brain tissue and often leads to death within a few weeks. It is caused by the human ...

Please provide your email address to receive an email when new articles are posted on . Researchers performed genetic analyses of 336 cases of those with PML, 94 of whom were patients with MS. Four ...

CE-VST01-JC is an allogeneic, off-the-shelf, T cell therapy targeting the JC virus, the cause of PML, a rare, rapidly progressing, often fatal illness for which there are no approved treatment options ...

ROCKVILLE, Md.--(BUSINESS WIRE)--NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced that the first patient has been dosed in the pilot ...